Brief: CervoMed's Neflamapimod gets U.S. FDA Orphan Drug Designation for treating Frontotemporal Dementia
27/11/2024 12:15
Nov 27 (Reuters) - CervoMed Inc CRVO.O :
* CERVOMED ANNOUNCES ORPHAN DRUG DESIGNATION GRANTED TO
NEFLAMAPIMOD BY U.S. FOOD AND DRUG ADMINISTRATION FOR THE
TREATMENT OF FRONTOTEMPORAL DEMENTIA
* CERVOMED INC - TO REPORT TOPLINE DATA FROM PHASE 2B DLB
TRIAL IN
DECEMBER 2024
Source text: ID:nGNX3pS5JY
Further company coverage: CRVO.O
((Reuters.Briefs@thomsonreuters.com;))